Replies to post #371760 on Anavex Life Sciences Corp (AVXL)

[tradeherpete]

Add Urano to the wgt club, I guess.

“It’s not so easy to control. If targeting the sigma 1 receptor improves behavioral phenotypes, then that’s actually clinically significant,” said Urano. But Urano still wants to know if this drug can treat other problems caused by Wolfram Syndrome such as diabetes and optic atrophy or if it treats only the behavioral symptoms addressed in the paper.

Anavex is going to be a busy Company in the coming years. I don’t know if it’s current Patents extend to every organ in the body, but they should.